Core Viewpoint - The National Health Commission of China has issued notifications prohibiting the use of two surgical procedures: "cervical deep lymphatic vessel/vein anastomosis" for Alzheimer's disease and "jejunum-ileum anastomosis" for type 2 diabetes treatment, due to concerns over their safety and efficacy [1][4][12]. Group 1: Alzheimer's Disease and Surgical Procedure - The "cervical deep lymphatic vessel/vein anastomosis" (LVA) is deemed to be in the early exploratory stage of clinical research, lacking clear indications and contraindications, as well as high-quality evidence supporting its safety and effectiveness [4][10]. - The procedure has been evaluated by experts, who concluded that its application in treating Alzheimer's disease is not supported by sufficient clinical evidence, and it poses potential risks that may outweigh benefits for patients with mild symptoms [9][10]. - The National Health Commission has mandated local health authorities to ensure that medical institutions cease the use of LVA for Alzheimer's treatment and to provide follow-up services for affected patients [11]. Group 2: Type 2 Diabetes and Surgical Procedure - The "jejunum-ileum anastomosis" has been evaluated and found to have uncertain safety and effectiveness for treating type 2 diabetes, with potential severe complications such as liver failure and malnutrition [12][14]. - Although some studies suggest that this procedure may improve blood sugar levels post-surgery, the overall clinical evidence remains limited, and it has not been included in the latest diabetes treatment guidelines [13][14]. - The National Health Commission has instructed health authorities to monitor and regulate the clinical application of this procedure, ensuring that institutions stop its use for diabetes treatment and enhance public health education [14].
国家卫健委叫停两项手术,涉阿尔茨海默病、糖尿病
21世纪经济报道·2025-07-09 10:06